‘It’s Incredibly Rare In A Career To Be In This Position’ – Sandoz CFO On Bio100 And The Path Ahead
In the wake of ambitious new long-term strategic targets revealed by Sandoz, the firm’s chief financial officer Remco Steenbergen talks to Generics Bulletin about how the company plans to achieve its targets of doubling sales by 2035 and building a portfolio of 100 biosimilars by 2040.
Generics Bulletin - September 16, 2026

Veracyte Completes Bladder Cancer Testing Loop With Third Urology Deal In Five Years
Veracyte has paid $150m for Convergent Genomics and its urine-based UroAmp platform, extending a portfolio that now spans tissue, blood and urine testing across bladder cancer.
Medtech Insight - September 16, 2026

New Kid On The Block: Renova Launches Its First Generics In The US
New Jersey-based Renova Pharmaceuticals made its US commercial debut with three generic drug launches – dimethyl sulfoxide irrigation, l-glutamine, and ascorbic acid injection.
Generics Bulletin - September 16, 2026

Samsung Bioepis Escapes Pfizer Damages Threat In Australia
Samsung Bioepis defeated Pfizer’s Australian Brenzys (etanercept) patent case, with the Federal Court finding no infringement and invalidating 13 of 14 asserted claims.
Generics Bulletin - September 16, 2026

Uniting Rx And Supplements Under One Brand: What Hypera’s GLP-1 Play Signals To The Companion Market
Brazil's Hypera has launched GLP-1 semaglutide and a companion dietary supplement range under the same brand name. Experts see significant opportunity for an “ecosystem” approach to the GLP-1 patient, but flag clinical credibility and regulatory transferability as key hurdles to global replication.
HBW Insight - September 16, 2026

Senlang/Tempest Option Marks China’s First Global Deal For In Vivo CAR-T
China’s Senlang reaches license option deal with Tempest for ex-China rights to a BCMA/GPRC5D-targeted in vivo CAR-T candidate delivered by a CD7-targeted lentiviral vector, plus its vector platform and other in vivo CAR-T assets.
Scrip - September 16, 2026

WCLC 2026: Leads Eyes Phase III For Novel Bispecific After Promising 1L NSCLC Data
Leads Biolabs’ anti-PD-L1/4-1BB bispecific combined with chemo achieved 71% ORR and 95% DCR in first-line, late-stage NSCLC in a China Phase II trial. The Chinese firm is upbeat about the outcomes although longer-term efficacy durability remains to be confirmed.
Scrip - September 16, 2026

Trump’s MFN Deals Reach 89% Of US Market As Benchmarking And Durability Remain In Doubt
The voluntary deals now reach most of the US branded market even as the scope of each agreement remains somewhat opaque. Meanwhile, the foreign price increases the policy implicitly relies on have refused to materialize.
In Vivo - September 16, 2026

US FDA Warning To Bausch + Lomb Suggests Potential For Recall, Production Interruption
Warning letter explains that both Rx and OTC products are made at B+L facility FDA officials inspected in March. FDA twice notes that recall would be needed if firm’s response to the warning isn’t satisfactory.
HBW Insight - September 16, 2026